The Fort Worth Press - US panel weighs authorizing Covid vaccines for youngest children

USD -
AED 3.672501
AFN 63.999831
ALL 80.878301
AMD 368.276037
ANG 1.789884
AOA 918.000144
ARS 1403.474607
AUD 1.384352
AWG 1.8025
AZN 1.696955
BAM 1.65809
BBD 2.008732
BDT 122.377178
BGN 1.668102
BHD 0.376584
BIF 2968.504938
BMD 1
BND 1.264635
BOB 6.891611
BRL 4.915095
BSD 0.997329
BTN 94.180832
BWP 13.389852
BYN 2.818448
BYR 19600
BZD 2.00585
CAD 1.368475
CDF 2265.00017
CHF 0.77835
CLF 0.022646
CLP 890.873638
CNY 6.80075
CNH 6.800445
COP 3727.014539
CRC 458.479929
CUC 1
CUP 26.5
CVE 93.480565
CZK 20.686003
DJF 177.601628
DKK 6.35788
DOP 59.310754
DZD 132.326735
EGP 52.926414
ERN 15
ETB 155.726591
EUR 0.850625
FJD 2.183003
FKP 0.733657
GBP 0.737028
GEL 2.675007
GGP 0.733657
GHS 11.234793
GIP 0.733657
GMD 73.498067
GNF 8750.794795
GTQ 7.614768
GYD 208.672799
HKD 7.82886
HNL 26.513501
HRK 6.393297
HTG 130.575219
HUF 301.89598
IDR 17377.45
ILS 2.901296
IMP 0.733657
INR 94.425499
IQD 1306.515196
IRR 1311499.999534
ISK 122.010318
JEP 0.733657
JMD 157.187063
JOD 0.708996
JPY 156.592025
KES 128.803357
KGS 87.420505
KHR 4001.526006
KMF 417.999804
KPW 899.999743
KRW 1461.809729
KWD 0.30766
KYD 0.831164
KZT 460.946971
LAK 21871.900301
LBP 89311.771438
LKR 321.097029
LRD 183.01047
LSL 16.361918
LTL 2.95274
LVL 0.604889
LYD 6.306642
MAD 9.121445
MDL 17.054809
MGA 4165.995507
MKD 52.252978
MMK 2099.442981
MNT 3580.105345
MOP 8.041456
MRU 39.863507
MUR 46.82008
MVR 15.394756
MWK 1729.049214
MXN 17.21386
MYR 3.920987
MZN 63.910028
NAD 16.361918
NGN 1364.999743
NIO 36.700437
NOK 9.219555
NPR 150.68967
NZD 1.683561
OMR 0.384681
PAB 0.997329
PEN 3.448264
PGK 4.404222
PHP 60.515039
PKR 277.958713
PLN 3.604205
PYG 6092.153787
QAR 3.645458
RON 4.426303
RSD 99.504048
RUB 74.495789
RWF 1462.082998
SAR 3.767486
SBD 8.019432
SCR 14.874401
SDG 600.502964
SEK 9.230855
SGD 1.267065
SHP 0.746601
SLE 24.650341
SLL 20969.496166
SOS 569.963122
SRD 37.39898
STD 20697.981008
STN 20.770633
SVC 8.727057
SYP 110.581023
SZL 16.351151
THB 32.202995
TJS 9.305159
TMT 3.5
TND 2.896867
TOP 2.40776
TRY 45.35987
TTD 6.759357
TWD 31.316002
TZS 2598.109449
UAH 43.809334
UGX 3737.018354
UYU 39.777881
UZS 12097.83392
VES 499.23597
VND 26308
VUV 117.263765
WST 2.707097
XAF 556.107838
XAG 0.012445
XAU 0.000212
XCD 2.70255
XCG 1.797465
XDR 0.69162
XOF 556.107838
XPF 101.106354
YER 238.625027
ZAR 16.451705
ZMK 9001.200733
ZMW 18.98775
ZWL 321.999592
  • CMSD

    0.1140

    23.534

    +0.48%

  • VOD

    0.5100

    16.2

    +3.15%

  • RYCEF

    -0.4100

    16.37

    -2.5%

  • AZN

    0.3300

    182.85

    +0.18%

  • BCE

    -0.4300

    24.14

    -1.78%

  • GSK

    -0.0900

    50.41

    -0.18%

  • RBGPF

    0.7000

    63.61

    +1.1%

  • RIO

    2.2700

    105.38

    +2.15%

  • CMSC

    0.1400

    23.11

    +0.61%

  • BCC

    -2.0900

    70.67

    -2.96%

  • NGG

    0.9800

    86.89

    +1.13%

  • RELX

    0.0759

    33.58

    +0.23%

  • BTI

    0.2000

    58.28

    +0.34%

  • BP

    -0.4700

    43.34

    -1.08%

  • JRI

    0.0000

    13.15

    0%

US panel weighs authorizing Covid vaccines for youngest children
US panel weighs authorizing Covid vaccines for youngest children / Photo: © AFP/File

US panel weighs authorizing Covid vaccines for youngest children

After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.

Text size:

Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.

Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."

Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.

Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.

They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.

Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.

But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.

There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.

White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.

Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.

Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.

Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.

Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."

H.Carroll--TFWP